nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—STK11—breast cancer	0.0751	0.179	CbGaD
Sunitinib—CHEK2—breast cancer	0.0484	0.115	CbGaD
Sunitinib—FGFR2—breast cancer	0.0451	0.107	CbGaD
Sunitinib—FGFR1—breast cancer	0.0451	0.107	CbGaD
Sunitinib—ALK—breast cancer	0.0431	0.103	CbGaD
Sunitinib—FLT1—breast cancer	0.0431	0.103	CbGaD
Sunitinib—CSF1R—breast cancer	0.0409	0.0972	CbGaD
Sunitinib—KDR—breast cancer	0.027	0.0643	CbGaD
Sunitinib—KIT—breast cancer	0.0255	0.0607	CbGaD
Sunitinib—ABCG2—breast cancer	0.0141	0.0336	CbGaD
Sunitinib—ABCC4—Fluorouracil—breast cancer	0.00783	0.0419	CbGbCtD
Sunitinib—CYP3A4—breast cancer	0.00706	0.0168	CbGaD
Sunitinib—CYP3A5—Lapatinib—breast cancer	0.00632	0.0338	CbGbCtD
Sunitinib—ABCC2—Tamoxifen—breast cancer	0.00632	0.0338	CbGbCtD
Sunitinib—ABCB1—breast cancer	0.00588	0.014	CbGaD
Sunitinib—ABCG2—Tamoxifen—breast cancer	0.00571	0.0306	CbGbCtD
Sunitinib—ABCB1—Toremifene—breast cancer	0.00564	0.0302	CbGbCtD
Sunitinib—ABCG2—Mitoxantrone—breast cancer	0.00557	0.0298	CbGbCtD
Sunitinib—ABCC2—Paclitaxel—breast cancer	0.00492	0.0263	CbGbCtD
Sunitinib—CYP3A4—Exemestane—breast cancer	0.00487	0.0261	CbGbCtD
Sunitinib—ABCC2—Irinotecan—breast cancer	0.00485	0.026	CbGbCtD
Sunitinib—ABCC2—Carboplatin—breast cancer	0.00463	0.0248	CbGbCtD
Sunitinib—ABCG2—Paclitaxel—breast cancer	0.00445	0.0238	CbGbCtD
Sunitinib—ABCG2—Irinotecan—breast cancer	0.00439	0.0235	CbGbCtD
Sunitinib—ABCC4—Methotrexate—breast cancer	0.00432	0.0231	CbGbCtD
Sunitinib—ABCC2—Vinblastine—breast cancer	0.00431	0.0231	CbGbCtD
Sunitinib—CYP3A7—Tamoxifen—breast cancer	0.00422	0.0226	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Tamoxifen—breast cancer	0.00422	0.0226	CbGbCtD
Sunitinib—ABCG2—Fluorouracil—breast cancer	0.00421	0.0225	CbGbCtD
Sunitinib—ABCG2—Carboplatin—breast cancer	0.00418	0.0224	CbGbCtD
Sunitinib—CYP3A4—Letrozole—breast cancer	0.00414	0.0222	CbGbCtD
Sunitinib—ABCB1—Lapatinib—breast cancer	0.00411	0.022	CbGbCtD
Sunitinib—CYP3A4—Anastrozole—breast cancer	0.00369	0.0198	CbGbCtD
Sunitinib—ABCC2—Docetaxel—breast cancer	0.00356	0.019	CbGbCtD
Sunitinib—CYP3A4—Toremifene—breast cancer	0.00338	0.0181	CbGbCtD
Sunitinib—CYP3A7—Paclitaxel—breast cancer	0.00328	0.0176	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Paclitaxel—breast cancer	0.00328	0.0176	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Irinotecan—breast cancer	0.00324	0.0173	CbGbCtD
Sunitinib—CYP3A7—Irinotecan—breast cancer	0.00324	0.0173	CbGbCtD
Sunitinib—ABCG2—Docetaxel—breast cancer	0.00321	0.0172	CbGbCtD
Sunitinib—CYP3A5—Tamoxifen—breast cancer	0.00317	0.0169	CbGbCtD
Sunitinib—CYP3A4—Fulvestrant—breast cancer	0.00314	0.0168	CbGbCtD
Sunitinib—CYP3A4—Thiotepa—breast cancer	0.0028	0.015	CbGbCtD
Sunitinib—ABCC2—Doxorubicin—breast cancer	0.00265	0.0142	CbGbCtD
Sunitinib—ABCC2—Methotrexate—breast cancer	0.00257	0.0137	CbGbCtD
Sunitinib—CYP3A4—Ixabepilone—breast cancer	0.00256	0.0137	CbGbCtD
Sunitinib—CYP3A4—Lapatinib—breast cancer	0.00246	0.0132	CbGbCtD
Sunitinib—CYP3A5—Paclitaxel—breast cancer	0.00246	0.0132	CbGbCtD
Sunitinib—CYP3A5—Irinotecan—breast cancer	0.00243	0.013	CbGbCtD
Sunitinib—ABCG2—Doxorubicin—breast cancer	0.0024	0.0128	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Docetaxel—breast cancer	0.00237	0.0127	CbGbCtD
Sunitinib—CYP3A7—Docetaxel—breast cancer	0.00237	0.0127	CbGbCtD
Sunitinib—ABCG2—Methotrexate—breast cancer	0.00232	0.0124	CbGbCtD
Sunitinib—ABCB1—Vinorelbine—breast cancer	0.00228	0.0122	CbGbCtD
Sunitinib—ABCB1—Tamoxifen—breast cancer	0.00206	0.011	CbGbCtD
Sunitinib—ABCB1—Mitoxantrone—breast cancer	0.00201	0.0108	CbGbCtD
Sunitinib—CYP3A4—Raloxifene—breast cancer	0.00187	0.01	CbGbCtD
Sunitinib—CYP3A5—Docetaxel—breast cancer	0.00178	0.00953	CbGbCtD
Sunitinib—ABCB1—Gemcitabine—breast cancer	0.00177	0.0095	CbGbCtD
Sunitinib—ABCB1—Paclitaxel—breast cancer	0.0016	0.00858	CbGbCtD
Sunitinib—ABCB1—Irinotecan—breast cancer	0.00158	0.00847	CbGbCtD
Sunitinib—ABCB1—Vinblastine—breast cancer	0.00141	0.00753	CbGbCtD
Sunitinib—CYP3A4—Vinorelbine—breast cancer	0.00137	0.00732	CbGbCtD
Sunitinib—CYP3A4—Tamoxifen—breast cancer	0.00123	0.00661	CbGbCtD
Sunitinib—CYP3A4—Mitoxantrone—breast cancer	0.0012	0.00644	CbGbCtD
Sunitinib—ABCB1—Docetaxel—breast cancer	0.00116	0.0062	CbGbCtD
Sunitinib—CYP3A4—Paclitaxel—breast cancer	0.000961	0.00514	CbGbCtD
Sunitinib—CYP3A4—Irinotecan—breast cancer	0.000948	0.00507	CbGbCtD
Sunitinib—ABCB1—Doxorubicin—breast cancer	0.000864	0.00463	CbGbCtD
Sunitinib—CYP3A4—Vinblastine—breast cancer	0.000843	0.00451	CbGbCtD
Sunitinib—ABCB1—Methotrexate—breast cancer	0.000837	0.00448	CbGbCtD
Sunitinib—CYP3A4—Docetaxel—breast cancer	0.000695	0.00372	CbGbCtD
Sunitinib—Metoclopramide—CYP17A1—breast cancer	0.000551	0.261	CrCbGaD
Sunitinib—CYP3A4—Doxorubicin—breast cancer	0.000518	0.00277	CbGbCtD
Sunitinib—Procainamide—DNMT1—breast cancer	0.000511	0.242	CrCbGaD
Sunitinib—Procainamide—SCN10A—breast cancer	0.000317	0.15	CrCbGaD
Sunitinib—Procainamide—ACHE—breast cancer	0.000302	0.143	CrCbGaD
Sunitinib—FGFR2—Estradiol—Fulvestrant—breast cancer	0.00024	0.0948	CbGdCrCtD
Sunitinib—Procainamide—BCHE—breast cancer	0.000178	0.0842	CrCbGaD
Sunitinib—Metoclopramide—CYP2D6—breast cancer	0.000153	0.0728	CrCbGaD
Sunitinib—DYRK1A—Topotecan—Irinotecan—breast cancer	0.000153	0.0607	CbGdCrCtD
Sunitinib—TLK2—Progesterone—Fluoxymesterone—breast cancer	0.000135	0.0534	CbGdCrCtD
Sunitinib—CHEK2—Docetaxel—Paclitaxel—breast cancer	0.00013	0.0514	CbGdCrCtD
Sunitinib—PLK4—Topotecan—Irinotecan—breast cancer	0.000105	0.0415	CbGdCrCtD
Sunitinib—Procainamide—CYP2D6—breast cancer	9.75e-05	0.0462	CrCbGaD
Sunitinib—MAP4K4—Testosterone Propionate—Fluoxymesterone—breast cancer	9.31e-05	0.0368	CbGdCrCtD
Sunitinib—CHEK2—Vindesine—Vinorelbine—breast cancer	8.26e-05	0.0327	CbGdCrCtD
Sunitinib—DYRK1A—Doxorubicin—Idarubicin—breast cancer	7.86e-05	0.0311	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Idarubicin—breast cancer	7.86e-05	0.0311	CbGdCrCtD
Sunitinib—DYRK1A—Epirubicin—Idarubicin—breast cancer	7.86e-05	0.0311	CbGdCrCtD
Sunitinib—PRPF4—Daunorubicin—Idarubicin—breast cancer	6.78e-05	0.0268	CbGdCrCtD
Sunitinib—CAMK2G—Azacitidine—Gemcitabine—breast cancer	6.72e-05	0.0266	CbGdCrCtD
Sunitinib—CHEK2—Vindesine—Vinblastine—breast cancer	6.6e-05	0.0261	CbGdCrCtD
Sunitinib—CHEK2—Paclitaxel—Docetaxel—breast cancer	6.48e-05	0.0257	CbGdCrCtD
Sunitinib—IRAK1—bone marrow—breast cancer	6.31e-05	0.000656	CbGeAlD
Sunitinib—MAP3K7—female gonad—breast cancer	6.28e-05	0.000653	CbGeAlD
Sunitinib—PRPF4B—lymph node—breast cancer	6.28e-05	0.000653	CbGeAlD
Sunitinib—FLT1—pituitary gland—breast cancer	6.27e-05	0.000652	CbGeAlD
Sunitinib—PTK2B—endocrine gland—breast cancer	6.27e-05	0.000652	CbGeAlD
Sunitinib—FLT4—endocrine gland—breast cancer	6.25e-05	0.00065	CbGeAlD
Sunitinib—FLT1—adipose tissue—breast cancer	6.25e-05	0.00065	CbGeAlD
Sunitinib—TBK1—female gonad—breast cancer	6.21e-05	0.000645	CbGeAlD
Sunitinib—EPHB6—pituitary gland—breast cancer	6.2e-05	0.000645	CbGeAlD
Sunitinib—FGFR2—female reproductive system—breast cancer	6.2e-05	0.000644	CbGeAlD
Sunitinib—RPS6KB1—bone marrow—breast cancer	6.19e-05	0.000644	CbGeAlD
Sunitinib—STK39—lymph node—breast cancer	6.19e-05	0.000644	CbGeAlD
Sunitinib—EPHB6—adipose tissue—breast cancer	6.18e-05	0.000642	CbGeAlD
Sunitinib—CSNK1E—endocrine gland—breast cancer	6.17e-05	0.000641	CbGeAlD
Sunitinib—TYK2—female gonad—breast cancer	6.16e-05	0.000641	CbGeAlD
Sunitinib—JAK2—female reproductive system—breast cancer	6.16e-05	0.000641	CbGeAlD
Sunitinib—FGR—bone marrow—breast cancer	6.16e-05	0.00064	CbGeAlD
Sunitinib—CSNK2A1—lymph node—breast cancer	6.11e-05	0.000635	CbGeAlD
Sunitinib—YES1—uterus—breast cancer	6.1e-05	0.000635	CbGeAlD
Sunitinib—SLK—adrenal gland—breast cancer	6.1e-05	0.000634	CbGeAlD
Sunitinib—IRAK1—female gonad—breast cancer	6.08e-05	0.000633	CbGeAlD
Sunitinib—FYN—female reproductive system—breast cancer	6.08e-05	0.000632	CbGeAlD
Sunitinib—CSF1R—skin of body—breast cancer	6.07e-05	0.000631	CbGeAlD
Sunitinib—STK10—uterus—breast cancer	6.05e-05	0.000629	CbGeAlD
Sunitinib—FGFR2—adrenal gland—breast cancer	6.05e-05	0.000629	CbGeAlD
Sunitinib—MYLK—lymph node—breast cancer	6.03e-05	0.000627	CbGeAlD
Sunitinib—TAOK3—uterus—breast cancer	6.02e-05	0.000626	CbGeAlD
Sunitinib—JAK2—adrenal gland—breast cancer	6.01e-05	0.000625	CbGeAlD
Sunitinib—YES1—pituitary gland—breast cancer	5.99e-05	0.000623	CbGeAlD
Sunitinib—PDGFRA—uterus—breast cancer	5.99e-05	0.000622	CbGeAlD
Sunitinib—RPS6KB1—female gonad—breast cancer	5.97e-05	0.000621	CbGeAlD
Sunitinib—YES1—adipose tissue—breast cancer	5.97e-05	0.000621	CbGeAlD
Sunitinib—PLK4—lymph node—breast cancer	5.96e-05	0.000619	CbGeAlD
Sunitinib—MAP3K3—female reproductive system—breast cancer	5.94e-05	0.000618	CbGeAlD
Sunitinib—MAP4K5—female reproductive system—breast cancer	5.94e-05	0.000618	CbGeAlD
Sunitinib—MAP2K2—endocrine gland—breast cancer	5.94e-05	0.000617	CbGeAlD
Sunitinib—ULK3—endocrine gland—breast cancer	5.94e-05	0.000617	CbGeAlD
Sunitinib—FGR—female gonad—breast cancer	5.93e-05	0.000617	CbGeAlD
Sunitinib—FYN—adrenal gland—breast cancer	5.93e-05	0.000617	CbGeAlD
Sunitinib—STK4—lymph node—breast cancer	5.92e-05	0.000616	CbGeAlD
Sunitinib—TAOK3—pituitary gland—breast cancer	5.92e-05	0.000615	CbGeAlD
Sunitinib—STK10—adipose tissue—breast cancer	5.91e-05	0.000615	CbGeAlD
Sunitinib—AXL—female gonad—breast cancer	5.91e-05	0.000614	CbGeAlD
Sunitinib—SLK—bone marrow—breast cancer	5.9e-05	0.000614	CbGeAlD
Sunitinib—MAP3K2—endocrine gland—breast cancer	5.89e-05	0.000613	CbGeAlD
Sunitinib—TAOK3—adipose tissue—breast cancer	5.89e-05	0.000613	CbGeAlD
Sunitinib—KDR—endometrium—breast cancer	5.86e-05	0.000609	CbGeAlD
Sunitinib—MAP2K5—endometrium—breast cancer	5.86e-05	0.000609	CbGeAlD
Sunitinib—PDGFRA—adipose tissue—breast cancer	5.86e-05	0.000609	CbGeAlD
Sunitinib—JAK2—bone marrow—breast cancer	5.82e-05	0.000605	CbGeAlD
Sunitinib—PHKG2—lymph node—breast cancer	5.82e-05	0.000605	CbGeAlD
Sunitinib—MAP4K5—adrenal gland—breast cancer	5.8e-05	0.000603	CbGeAlD
Sunitinib—MAP3K3—adrenal gland—breast cancer	5.8e-05	0.000603	CbGeAlD
Sunitinib—KIT—epithelium—breast cancer	5.79e-05	0.000602	CbGeAlD
Sunitinib—STK24—lymph node—breast cancer	5.78e-05	0.000601	CbGeAlD
Sunitinib—TBK1—endocrine gland—breast cancer	5.77e-05	0.0006	CbGeAlD
Sunitinib—FLT1—female reproductive system—breast cancer	5.74e-05	0.000597	CbGeAlD
Sunitinib—FYN—bone marrow—breast cancer	5.74e-05	0.000597	CbGeAlD
Sunitinib—TYK2—endocrine gland—breast cancer	5.73e-05	0.000596	CbGeAlD
Sunitinib—CSF1R—endometrium—breast cancer	5.72e-05	0.000595	CbGeAlD
Sunitinib—DAPK2—lymph node—breast cancer	5.72e-05	0.000594	CbGeAlD
Sunitinib—SLK—female gonad—breast cancer	5.69e-05	0.000592	CbGeAlD
Sunitinib—PDGFRB—epithelium—breast cancer	5.66e-05	0.000588	CbGeAlD
Sunitinib—FGFR2—female gonad—breast cancer	5.64e-05	0.000586	CbGeAlD
Sunitinib—STK16—lymph node—breast cancer	5.62e-05	0.000585	CbGeAlD
Sunitinib—JAK2—female gonad—breast cancer	5.61e-05	0.000583	CbGeAlD
Sunitinib—MAP4K5—bone marrow—breast cancer	5.61e-05	0.000583	CbGeAlD
Sunitinib—MAP3K3—bone marrow—breast cancer	5.61e-05	0.000583	CbGeAlD
Sunitinib—FLT1—adrenal gland—breast cancer	5.6e-05	0.000583	CbGeAlD
Sunitinib—HIPK3—lymph node—breast cancer	5.6e-05	0.000582	CbGeAlD
Sunitinib—HIPK2—lymph node—breast cancer	5.6e-05	0.000582	CbGeAlD
Sunitinib—ALK—lymph node—breast cancer	5.6e-05	0.000582	CbGeAlD
Sunitinib—RPS6KB1—endocrine gland—breast cancer	5.55e-05	0.000577	CbGeAlD
Sunitinib—EPHB6—adrenal gland—breast cancer	5.54e-05	0.000576	CbGeAlD
Sunitinib—RIOK2—lymph node—breast cancer	5.54e-05	0.000576	CbGeAlD
Sunitinib—TNK1—lymph node—breast cancer	5.54e-05	0.000576	CbGeAlD
Sunitinib—FYN—female gonad—breast cancer	5.53e-05	0.000575	CbGeAlD
Sunitinib—FGR—endocrine gland—breast cancer	5.52e-05	0.000574	CbGeAlD
Sunitinib—RET—endocrine gland—breast cancer	5.52e-05	0.000574	CbGeAlD
Sunitinib—KIT—skin of body—breast cancer	5.51e-05	0.000573	CbGeAlD
Sunitinib—AXL—endocrine gland—breast cancer	5.5e-05	0.000571	CbGeAlD
Sunitinib—YES1—female reproductive system—breast cancer	5.49e-05	0.00057	CbGeAlD
Sunitinib—MAP4K1—lymph node—breast cancer	5.48e-05	0.00057	CbGeAlD
Sunitinib—STK10—female reproductive system—breast cancer	5.44e-05	0.000565	CbGeAlD
Sunitinib—TAOK3—female reproductive system—breast cancer	5.42e-05	0.000563	CbGeAlD
Sunitinib—MAP4K5—female gonad—breast cancer	5.41e-05	0.000562	CbGeAlD
Sunitinib—MAP3K3—female gonad—breast cancer	5.41e-05	0.000562	CbGeAlD
Sunitinib—KDR—uterus—breast cancer	5.4e-05	0.000562	CbGeAlD
Sunitinib—PDGFRA—female reproductive system—breast cancer	5.38e-05	0.00056	CbGeAlD
Sunitinib—PDGFRB—skin of body—breast cancer	5.38e-05	0.000559	CbGeAlD
Sunitinib—DAPK3—lymph node—breast cancer	5.38e-05	0.000559	CbGeAlD
Sunitinib—PLK4—Epirubicin—Idarubicin—breast cancer	5.37e-05	0.0212	CbGdCrCtD
Sunitinib—PLK4—Doxorubicin—Idarubicin—breast cancer	5.37e-05	0.0212	CbGdCrCtD
Sunitinib—YES1—adrenal gland—breast cancer	5.35e-05	0.000557	CbGeAlD
Sunitinib—CLK2—lymph node—breast cancer	5.33e-05	0.000554	CbGeAlD
Sunitinib—KCNH2—nipple—breast cancer	5.31e-05	0.000552	CbGeAlD
Sunitinib—STK10—adrenal gland—breast cancer	5.31e-05	0.000552	CbGeAlD
Sunitinib—KDR—pituitary gland—breast cancer	5.3e-05	0.000551	CbGeAlD
Sunitinib—MAP2K5—pituitary gland—breast cancer	5.3e-05	0.000551	CbGeAlD
Sunitinib—MAP4K2—lymph node—breast cancer	5.3e-05	0.000551	CbGeAlD
Sunitinib—TAOK3—adrenal gland—breast cancer	5.29e-05	0.00055	CbGeAlD
Sunitinib—KDR—adipose tissue—breast cancer	5.28e-05	0.000549	CbGeAlD
Sunitinib—MAP2K5—adipose tissue—breast cancer	5.28e-05	0.000549	CbGeAlD
Sunitinib—CYP3A7—endocrine gland—breast cancer	5.27e-05	0.000548	CbGeAlD
Sunitinib—CSF1R—uterus—breast cancer	5.27e-05	0.000548	CbGeAlD
Sunitinib—PDGFRA—adrenal gland—breast cancer	5.25e-05	0.000546	CbGeAlD
Sunitinib—FGFR2—endocrine gland—breast cancer	5.24e-05	0.000545	CbGeAlD
Sunitinib—STK3—lymph node—breast cancer	5.23e-05	0.000544	CbGeAlD
Sunitinib—FLT1—female gonad—breast cancer	5.23e-05	0.000543	CbGeAlD
Sunitinib—JAK2—endocrine gland—breast cancer	5.22e-05	0.000542	CbGeAlD
Sunitinib—KIT—endometrium—breast cancer	5.19e-05	0.00054	CbGeAlD
Sunitinib—YES1—bone marrow—breast cancer	5.18e-05	0.000539	CbGeAlD
Sunitinib—CSF1R—pituitary gland—breast cancer	5.18e-05	0.000538	CbGeAlD
Sunitinib—EPHB6—female gonad—breast cancer	5.17e-05	0.000537	CbGeAlD
Sunitinib—CSF1R—adipose tissue—breast cancer	5.15e-05	0.000536	CbGeAlD
Sunitinib—FYN—endocrine gland—breast cancer	5.14e-05	0.000535	CbGeAlD
Sunitinib—STK10—bone marrow—breast cancer	5.13e-05	0.000534	CbGeAlD
Sunitinib—TAOK3—bone marrow—breast cancer	5.11e-05	0.000532	CbGeAlD
Sunitinib—PDGFRB—endometrium—breast cancer	5.07e-05	0.000527	CbGeAlD
Sunitinib—DYRK1A—lymph node—breast cancer	5.03e-05	0.000523	CbGeAlD
Sunitinib—MAP4K5—endocrine gland—breast cancer	5.03e-05	0.000523	CbGeAlD
Sunitinib—MAP3K3—endocrine gland—breast cancer	5.03e-05	0.000523	CbGeAlD
Sunitinib—YES1—female gonad—breast cancer	4.99e-05	0.000519	CbGeAlD
Sunitinib—STK10—female gonad—breast cancer	4.95e-05	0.000514	CbGeAlD
Sunitinib—TAOK3—female gonad—breast cancer	4.93e-05	0.000512	CbGeAlD
Sunitinib—MERTK—lymph node—breast cancer	4.92e-05	0.000511	CbGeAlD
Sunitinib—PDGFRA—female gonad—breast cancer	4.9e-05	0.000509	CbGeAlD
Sunitinib—FLT1—endocrine gland—breast cancer	4.86e-05	0.000505	CbGeAlD
Sunitinib—KDR—female reproductive system—breast cancer	4.85e-05	0.000505	CbGeAlD
Sunitinib—MAP2K5—female reproductive system—breast cancer	4.85e-05	0.000505	CbGeAlD
Sunitinib—MAP4K4—lymph node—breast cancer	4.83e-05	0.000502	CbGeAlD
Sunitinib—NUAK2—lymph node—breast cancer	4.79e-05	0.000498	CbGeAlD
Sunitinib—KIT—uterus—breast cancer	4.79e-05	0.000498	CbGeAlD
Sunitinib—MAP3K12—lymph node—breast cancer	4.76e-05	0.000495	CbGeAlD
Sunitinib—FLT3—lymph node—breast cancer	4.76e-05	0.000495	CbGeAlD
Sunitinib—CSF1R—female reproductive system—breast cancer	4.74e-05	0.000493	CbGeAlD
Sunitinib—KDR—adrenal gland—breast cancer	4.74e-05	0.000493	CbGeAlD
Sunitinib—MAP2K5—adrenal gland—breast cancer	4.74e-05	0.000493	CbGeAlD
Sunitinib—CHEK2—Epirubicin—Idarubicin—breast cancer	4.73e-05	0.0187	CbGdCrCtD
Sunitinib—CHEK2—Doxorubicin—Idarubicin—breast cancer	4.73e-05	0.0187	CbGdCrCtD
Sunitinib—KIT—pituitary gland—breast cancer	4.7e-05	0.000489	CbGeAlD
Sunitinib—RPS6KA3—lymph node—breast cancer	4.69e-05	0.000488	CbGeAlD
Sunitinib—KIT—adipose tissue—breast cancer	4.68e-05	0.000487	CbGeAlD
Sunitinib—PDGFRB—uterus—breast cancer	4.67e-05	0.000486	CbGeAlD
Sunitinib—MAP2K1—lymph node—breast cancer	4.66e-05	0.000485	CbGeAlD
Sunitinib—YES1—endocrine gland—breast cancer	4.64e-05	0.000483	CbGeAlD
Sunitinib—CSF1R—adrenal gland—breast cancer	4.62e-05	0.000481	CbGeAlD
Sunitinib—STK10—endocrine gland—breast cancer	4.6e-05	0.000478	CbGeAlD
Sunitinib—CSNK1A1—lymph node—breast cancer	4.6e-05	0.000478	CbGeAlD
Sunitinib—PDGFRB—pituitary gland—breast cancer	4.59e-05	0.000477	CbGeAlD
Sunitinib—KDR—bone marrow—breast cancer	4.58e-05	0.000477	CbGeAlD
Sunitinib—TAOK3—endocrine gland—breast cancer	4.58e-05	0.000477	CbGeAlD
Sunitinib—PDGFRB—adipose tissue—breast cancer	4.57e-05	0.000475	CbGeAlD
Sunitinib—CLK1—lymph node—breast cancer	4.57e-05	0.000475	CbGeAlD
Sunitinib—PDGFRA—endocrine gland—breast cancer	4.55e-05	0.000474	CbGeAlD
Sunitinib—CAMK2G—lymph node—breast cancer	4.49e-05	0.000466	CbGeAlD
Sunitinib—BMP2K—lymph node—breast cancer	4.49e-05	0.000466	CbGeAlD
Sunitinib—CSF1R—bone marrow—breast cancer	4.47e-05	0.000465	CbGeAlD
Sunitinib—CHEK2—Vincristine—Vinorelbine—breast cancer	4.46e-05	0.0176	CbGdCrCtD
Sunitinib—LRRK2—lymph node—breast cancer	4.45e-05	0.000462	CbGeAlD
Sunitinib—KDR—female gonad—breast cancer	4.42e-05	0.000459	CbGeAlD
Sunitinib—MAP2K5—female gonad—breast cancer	4.42e-05	0.000459	CbGeAlD
Sunitinib—PRKAA1—lymph node—breast cancer	4.38e-05	0.000456	CbGeAlD
Sunitinib—PTK2B—lymph node—breast cancer	4.33e-05	0.000451	CbGeAlD
Sunitinib—FLT4—lymph node—breast cancer	4.32e-05	0.000449	CbGeAlD
Sunitinib—CSF1R—female gonad—breast cancer	4.31e-05	0.000448	CbGeAlD
Sunitinib—KIT—female reproductive system—breast cancer	4.3e-05	0.000447	CbGeAlD
Sunitinib—CSNK1E—lymph node—breast cancer	4.26e-05	0.000443	CbGeAlD
Sunitinib—FGFR1—lymph node—breast cancer	4.26e-05	0.000443	CbGeAlD
Sunitinib—CSNK1E—Danazol—Fluoxymesterone—breast cancer	4.24e-05	0.0168	CbGdCrCtD
Sunitinib—PDGFRB—female reproductive system—breast cancer	4.2e-05	0.000437	CbGeAlD
Sunitinib—KIT—adrenal gland—breast cancer	4.2e-05	0.000437	CbGeAlD
Sunitinib—IRAK4—lymph node—breast cancer	4.2e-05	0.000436	CbGeAlD
Sunitinib—CHEK2—Vinorelbine—Vinblastine—breast cancer	4.17e-05	0.0165	CbGdCrCtD
Sunitinib—KDR—endocrine gland—breast cancer	4.11e-05	0.000427	CbGeAlD
Sunitinib—MAP2K5—endocrine gland—breast cancer	4.11e-05	0.000427	CbGeAlD
Sunitinib—ULK3—lymph node—breast cancer	4.1e-05	0.000427	CbGeAlD
Sunitinib—MAP2K2—lymph node—breast cancer	4.1e-05	0.000427	CbGeAlD
Sunitinib—PDGFRB—adrenal gland—breast cancer	4.1e-05	0.000426	CbGeAlD
Sunitinib—MAP3K2—lymph node—breast cancer	4.07e-05	0.000424	CbGeAlD
Sunitinib—KIT—bone marrow—breast cancer	4.06e-05	0.000422	CbGeAlD
Sunitinib—MAP3K7—lymph node—breast cancer	4.04e-05	0.00042	CbGeAlD
Sunitinib—CSF1R—endocrine gland—breast cancer	4.01e-05	0.000417	CbGeAlD
Sunitinib—TBK1—lymph node—breast cancer	3.99e-05	0.000415	CbGeAlD
Sunitinib—PDGFRB—bone marrow—breast cancer	3.97e-05	0.000412	CbGeAlD
Sunitinib—TYK2—lymph node—breast cancer	3.96e-05	0.000412	CbGeAlD
Sunitinib—KIT—female gonad—breast cancer	3.91e-05	0.000407	CbGeAlD
Sunitinib—IRAK1—lymph node—breast cancer	3.91e-05	0.000407	CbGeAlD
Sunitinib—RPS6KB1—lymph node—breast cancer	3.84e-05	0.000399	CbGeAlD
Sunitinib—PDGFRB—female gonad—breast cancer	3.82e-05	0.000398	CbGeAlD
Sunitinib—FGR—lymph node—breast cancer	3.81e-05	0.000397	CbGeAlD
Sunitinib—RET—lymph node—breast cancer	3.81e-05	0.000397	CbGeAlD
Sunitinib—AXL—lymph node—breast cancer	3.8e-05	0.000395	CbGeAlD
Sunitinib—ABCC4—uterus—breast cancer	3.72e-05	0.000387	CbGeAlD
Sunitinib—SLK—lymph node—breast cancer	3.66e-05	0.00038	CbGeAlD
Sunitinib—KIT—endocrine gland—breast cancer	3.64e-05	0.000379	CbGeAlD
Sunitinib—ABCC4—adipose tissue—breast cancer	3.64e-05	0.000378	CbGeAlD
Sunitinib—PRPF4—Promazine—Tamoxifen—breast cancer	3.63e-05	0.0144	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Epirubicin—breast cancer	3.61e-05	0.0143	CbGdCrCtD
Sunitinib—DYRK1A—Doxorubicin—Epirubicin—breast cancer	3.61e-05	0.0143	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Epirubicin—breast cancer	3.61e-05	0.0143	CbGdCrCtD
Sunitinib—JAK2—lymph node—breast cancer	3.61e-05	0.000375	CbGeAlD
Sunitinib—CHEK2—Vinblastine—Vinorelbine—breast cancer	3.58e-05	0.0142	CbGdCrCtD
Sunitinib—CHEK2—Vincristine—Vinblastine—breast cancer	3.56e-05	0.0141	CbGdCrCtD
Sunitinib—PDGFRB—endocrine gland—breast cancer	3.56e-05	0.00037	CbGeAlD
Sunitinib—FYN—lymph node—breast cancer	3.56e-05	0.00037	CbGeAlD
Sunitinib—MAP4K5—lymph node—breast cancer	3.47e-05	0.000361	CbGeAlD
Sunitinib—MAP3K3—lymph node—breast cancer	3.47e-05	0.000361	CbGeAlD
Sunitinib—RPS6KA1—Azacitidine—Gemcitabine—breast cancer	3.44e-05	0.0136	CbGdCrCtD
Sunitinib—FLT1—lymph node—breast cancer	3.36e-05	0.000349	CbGeAlD
Sunitinib—ABCC4—female reproductive system—breast cancer	3.35e-05	0.000348	CbGeAlD
Sunitinib—DYRK1A—Daunorubicin—Doxorubicin—breast cancer	3.34e-05	0.0132	CbGdCrCtD
Sunitinib—DYRK1A—Epirubicin—Doxorubicin—breast cancer	3.34e-05	0.0132	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Doxorubicin—breast cancer	3.34e-05	0.0132	CbGdCrCtD
Sunitinib—EPHB6—lymph node—breast cancer	3.32e-05	0.000345	CbGeAlD
Sunitinib—ABCC4—adrenal gland—breast cancer	3.27e-05	0.00034	CbGeAlD
Sunitinib—ABCC2—female reproductive system—breast cancer	3.24e-05	0.000337	CbGeAlD
Sunitinib—YES1—lymph node—breast cancer	3.21e-05	0.000334	CbGeAlD
Sunitinib—KCNH2—endometrium—breast cancer	3.21e-05	0.000333	CbGeAlD
Sunitinib—STK10—lymph node—breast cancer	3.18e-05	0.000331	CbGeAlD
Sunitinib—TAOK3—lymph node—breast cancer	3.17e-05	0.000329	CbGeAlD
Sunitinib—ABCC2—adrenal gland—breast cancer	3.16e-05	0.000329	CbGeAlD
Sunitinib—ABCC4—bone marrow—breast cancer	3.16e-05	0.000328	CbGeAlD
Sunitinib—PDGFRA—lymph node—breast cancer	3.15e-05	0.000327	CbGeAlD
Sunitinib—PRPF4—Daunorubicin—Epirubicin—breast cancer	3.11e-05	0.0123	CbGdCrCtD
Sunitinib—PRPF4—Idarubicin—Epirubicin—breast cancer	3.11e-05	0.0123	CbGdCrCtD
Sunitinib—ABCC4—female gonad—breast cancer	3.04e-05	0.000317	CbGeAlD
Sunitinib—KCNH2—uterus—breast cancer	2.95e-05	0.000307	CbGeAlD
Sunitinib—KCNH2—pituitary gland—breast cancer	2.9e-05	0.000302	CbGeAlD
Sunitinib—PRPF4—Idarubicin—Doxorubicin—breast cancer	2.88e-05	0.0114	CbGdCrCtD
Sunitinib—PRPF4—Daunorubicin—Doxorubicin—breast cancer	2.88e-05	0.0114	CbGdCrCtD
Sunitinib—ABCG2—endometrium—breast cancer	2.85e-05	0.000296	CbGeAlD
Sunitinib—MAP2K5—lymph node—breast cancer	2.84e-05	0.000295	CbGeAlD
Sunitinib—KDR—lymph node—breast cancer	2.84e-05	0.000295	CbGeAlD
Sunitinib—ABCC4—endocrine gland—breast cancer	2.83e-05	0.000294	CbGeAlD
Sunitinib—PRPF4—Norethindrone—Fluoxymesterone—breast cancer	2.8e-05	0.0111	CbGdCrCtD
Sunitinib—CSF1R—lymph node—breast cancer	2.77e-05	0.000288	CbGeAlD
Sunitinib—ABCC2—endocrine gland—breast cancer	2.74e-05	0.000285	CbGeAlD
Sunitinib—CSNK1E—Betamethasone—Fluoxymesterone—breast cancer	2.71e-05	0.0107	CbGdCrCtD
Sunitinib—CSNK1E—Dexamethasone—Fluoxymesterone—breast cancer	2.71e-05	0.0107	CbGdCrCtD
Sunitinib—KCNH2—female reproductive system—breast cancer	2.65e-05	0.000276	CbGeAlD
Sunitinib—ABCG2—uterus—breast cancer	2.63e-05	0.000273	CbGeAlD
Sunitinib—CHEK2—Testosterone Propionate—Fluoxymesterone—breast cancer	2.61e-05	0.0103	CbGdCrCtD
Sunitinib—KCNH2—adrenal gland—breast cancer	2.59e-05	0.000269	CbGeAlD
Sunitinib—ABCG2—pituitary gland—breast cancer	2.58e-05	0.000268	CbGeAlD
Sunitinib—ABCG2—adipose tissue—breast cancer	2.57e-05	0.000267	CbGeAlD
Sunitinib—KIT—lymph node—breast cancer	2.52e-05	0.000262	CbGeAlD
Sunitinib—KCNH2—bone marrow—breast cancer	2.51e-05	0.000261	CbGeAlD
Sunitinib—PLK4—Idarubicin—Epirubicin—breast cancer	2.46e-05	0.00975	CbGdCrCtD
Sunitinib—PLK4—Doxorubicin—Epirubicin—breast cancer	2.46e-05	0.00975	CbGdCrCtD
Sunitinib—PDGFRB—lymph node—breast cancer	2.46e-05	0.000256	CbGeAlD
Sunitinib—KCNH2—female gonad—breast cancer	2.42e-05	0.000251	CbGeAlD
Sunitinib—CYP3A5—adipose tissue—breast cancer	2.39e-05	0.000248	CbGeAlD
Sunitinib—ABCG2—adrenal gland—breast cancer	2.3e-05	0.00024	CbGeAlD
Sunitinib—PLK4—Epirubicin—Doxorubicin—breast cancer	2.28e-05	0.00902	CbGdCrCtD
Sunitinib—PLK4—Idarubicin—Doxorubicin—breast cancer	2.28e-05	0.00902	CbGdCrCtD
Sunitinib—KCNH2—endocrine gland—breast cancer	2.25e-05	0.000234	CbGeAlD
Sunitinib—ABCG2—bone marrow—breast cancer	2.23e-05	0.000232	CbGeAlD
Sunitinib—CHEK2—Doxorubicin—Epirubicin—breast cancer	2.17e-05	0.00859	CbGdCrCtD
Sunitinib—CHEK2—Danazol—Fluoxymesterone—breast cancer	2.17e-05	0.00859	CbGdCrCtD
Sunitinib—ABCG2—female gonad—breast cancer	2.15e-05	0.000223	CbGeAlD
Sunitinib—CHEK2—Epirubicin—Doxorubicin—breast cancer	2.01e-05	0.00795	CbGdCrCtD
Sunitinib—CYP3A5—female gonad—breast cancer	1.99e-05	0.000207	CbGeAlD
Sunitinib—ABCC4—lymph node—breast cancer	1.96e-05	0.000204	CbGeAlD
Sunitinib—CHEK2—Norethindrone—Fluoxymesterone—breast cancer	1.96e-05	0.00774	CbGdCrCtD
Sunitinib—ABCB1—embryo—breast cancer	1.92e-05	0.0002	CbGeAlD
Sunitinib—ABCC2—lymph node—breast cancer	1.89e-05	0.000197	CbGeAlD
Sunitinib—CYP3A5—endocrine gland—breast cancer	1.86e-05	0.000193	CbGeAlD
Sunitinib—CYP3A4—female reproductive system—breast cancer	1.65e-05	0.000171	CbGeAlD
Sunitinib—ABCB1—epithelium—breast cancer	1.57e-05	0.000163	CbGeAlD
Sunitinib—KCNH2—lymph node—breast cancer	1.55e-05	0.000161	CbGeAlD
Sunitinib—ABCB1—endometrium—breast cancer	1.41e-05	0.000146	CbGeAlD
Sunitinib—CYP3A4—endocrine gland—breast cancer	1.39e-05	0.000145	CbGeAlD
Sunitinib—Body temperature increased—Paclitaxel—breast cancer	1.39e-05	0.000103	CcSEcCtD
Sunitinib—Urethral disorder—Epirubicin—breast cancer	1.38e-05	0.000102	CcSEcCtD
Sunitinib—ABCG2—lymph node—breast cancer	1.38e-05	0.000144	CbGeAlD
Sunitinib—Hepatobiliary disease—Doxorubicin—breast cancer	1.38e-05	0.000102	CcSEcCtD
Sunitinib—Epistaxis—Doxorubicin—breast cancer	1.37e-05	0.000101	CcSEcCtD
Sunitinib—Anorexia—Capecitabine—breast cancer	1.37e-05	0.000101	CcSEcCtD
Sunitinib—Angiopathy—Methotrexate—breast cancer	1.37e-05	0.000101	CcSEcCtD
Sunitinib—Vomiting—Mitoxantrone—breast cancer	1.37e-05	0.000101	CcSEcCtD
Sunitinib—Vomiting—Irinotecan—breast cancer	1.37e-05	0.000101	CcSEcCtD
Sunitinib—Immune system disorder—Methotrexate—breast cancer	1.36e-05	0.000101	CcSEcCtD
Sunitinib—Dizziness—Fluorouracil—breast cancer	1.36e-05	0.000101	CcSEcCtD
Sunitinib—Mediastinal disorder—Methotrexate—breast cancer	1.36e-05	0.000101	CcSEcCtD
Sunitinib—Rash—Irinotecan—breast cancer	1.36e-05	0.0001	CcSEcCtD
Sunitinib—Rash—Mitoxantrone—breast cancer	1.36e-05	0.0001	CcSEcCtD
Sunitinib—Dermatitis—Mitoxantrone—breast cancer	1.35e-05	0.0001	CcSEcCtD
Sunitinib—Dermatitis—Irinotecan—breast cancer	1.35e-05	0.0001	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Docetaxel—breast cancer	1.35e-05	0.0001	CcSEcCtD
Sunitinib—Chills—Methotrexate—breast cancer	1.35e-05	0.0001	CcSEcCtD
Sunitinib—Headache—Irinotecan—breast cancer	1.35e-05	9.97e-05	CcSEcCtD
Sunitinib—Headache—Mitoxantrone—breast cancer	1.35e-05	9.97e-05	CcSEcCtD
Sunitinib—Insomnia—Docetaxel—breast cancer	1.34e-05	9.95e-05	CcSEcCtD
Sunitinib—Paraesthesia—Docetaxel—breast cancer	1.34e-05	9.87e-05	CcSEcCtD
Sunitinib—Erythema multiforme—Epirubicin—breast cancer	1.33e-05	9.87e-05	CcSEcCtD
Sunitinib—Alopecia—Methotrexate—breast cancer	1.33e-05	9.86e-05	CcSEcCtD
Sunitinib—Vomiting—Gemcitabine—breast cancer	1.33e-05	9.85e-05	CcSEcCtD
Sunitinib—Bradycardia—Doxorubicin—breast cancer	1.33e-05	9.83e-05	CcSEcCtD
Sunitinib—Dyspnoea—Docetaxel—breast cancer	1.33e-05	9.8e-05	CcSEcCtD
Sunitinib—Mental disorder—Methotrexate—breast cancer	1.32e-05	9.77e-05	CcSEcCtD
Sunitinib—Rash—Gemcitabine—breast cancer	1.32e-05	9.77e-05	CcSEcCtD
Sunitinib—Dermatitis—Gemcitabine—breast cancer	1.32e-05	9.76e-05	CcSEcCtD
Sunitinib—Eye disorder—Epirubicin—breast cancer	1.32e-05	9.76e-05	CcSEcCtD
Sunitinib—Malnutrition—Methotrexate—breast cancer	1.31e-05	9.71e-05	CcSEcCtD
Sunitinib—Erythema—Methotrexate—breast cancer	1.31e-05	9.71e-05	CcSEcCtD
Sunitinib—Haemoglobin—Doxorubicin—breast cancer	1.31e-05	9.71e-05	CcSEcCtD
Sunitinib—Headache—Gemcitabine—breast cancer	1.31e-05	9.71e-05	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Capecitabine—breast cancer	1.31e-05	9.7e-05	CcSEcCtD
Sunitinib—Cardiac disorder—Epirubicin—breast cancer	1.31e-05	9.69e-05	CcSEcCtD
Sunitinib—Flushing—Epirubicin—breast cancer	1.31e-05	9.69e-05	CcSEcCtD
Sunitinib—Vomiting—Fluorouracil—breast cancer	1.31e-05	9.69e-05	CcSEcCtD
Sunitinib—Dyspepsia—Docetaxel—breast cancer	1.31e-05	9.68e-05	CcSEcCtD
Sunitinib—Haemorrhage—Doxorubicin—breast cancer	1.31e-05	9.66e-05	CcSEcCtD
Sunitinib—Hepatitis—Doxorubicin—breast cancer	1.31e-05	9.66e-05	CcSEcCtD
Sunitinib—Insomnia—Capecitabine—breast cancer	1.3e-05	9.63e-05	CcSEcCtD
Sunitinib—Hypoaesthesia—Doxorubicin—breast cancer	1.3e-05	9.61e-05	CcSEcCtD
Sunitinib—Rash—Fluorouracil—breast cancer	1.3e-05	9.61e-05	CcSEcCtD
Sunitinib—Dermatitis—Fluorouracil—breast cancer	1.3e-05	9.6e-05	CcSEcCtD
Sunitinib—ABCB1—uterus—breast cancer	1.3e-05	0.000135	CbGeAlD
Sunitinib—Paraesthesia—Capecitabine—breast cancer	1.29e-05	9.56e-05	CcSEcCtD
Sunitinib—Decreased appetite—Docetaxel—breast cancer	1.29e-05	9.56e-05	CcSEcCtD
Sunitinib—Hypersensitivity—Paclitaxel—breast cancer	1.29e-05	9.56e-05	CcSEcCtD
Sunitinib—Headache—Fluorouracil—breast cancer	1.29e-05	9.54e-05	CcSEcCtD
Sunitinib—Urinary tract disorder—Doxorubicin—breast cancer	1.29e-05	9.54e-05	CcSEcCtD
Sunitinib—Oedema peripheral—Doxorubicin—breast cancer	1.29e-05	9.52e-05	CcSEcCtD
Sunitinib—Dysgeusia—Methotrexate—breast cancer	1.29e-05	9.51e-05	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Docetaxel—breast cancer	1.28e-05	9.49e-05	CcSEcCtD
Sunitinib—Connective tissue disorder—Doxorubicin—breast cancer	1.28e-05	9.49e-05	CcSEcCtD
Sunitinib—Dyspnoea—Capecitabine—breast cancer	1.28e-05	9.49e-05	CcSEcCtD
Sunitinib—Fatigue—Docetaxel—breast cancer	1.28e-05	9.48e-05	CcSEcCtD
Sunitinib—Angiopathy—Epirubicin—breast cancer	1.28e-05	9.47e-05	CcSEcCtD
Sunitinib—Urethral disorder—Doxorubicin—breast cancer	1.28e-05	9.47e-05	CcSEcCtD
Sunitinib—Nausea—Mitoxantrone—breast cancer	1.28e-05	9.45e-05	CcSEcCtD
Sunitinib—Nausea—Irinotecan—breast cancer	1.28e-05	9.45e-05	CcSEcCtD
Sunitinib—Immune system disorder—Epirubicin—breast cancer	1.28e-05	9.43e-05	CcSEcCtD
Sunitinib—ABCB1—pituitary gland—breast cancer	1.27e-05	0.000132	CbGeAlD
Sunitinib—Mediastinal disorder—Epirubicin—breast cancer	1.27e-05	9.41e-05	CcSEcCtD
Sunitinib—Pain—Docetaxel—breast cancer	1.27e-05	9.4e-05	CcSEcCtD
Sunitinib—Constipation—Docetaxel—breast cancer	1.27e-05	9.4e-05	CcSEcCtD
Sunitinib—Back pain—Methotrexate—breast cancer	1.27e-05	9.39e-05	CcSEcCtD
Sunitinib—Dyspepsia—Capecitabine—breast cancer	1.27e-05	9.37e-05	CcSEcCtD
Sunitinib—ABCB1—adipose tissue—breast cancer	1.27e-05	0.000132	CbGeAlD
Sunitinib—Chills—Epirubicin—breast cancer	1.27e-05	9.37e-05	CcSEcCtD
Sunitinib—Arrhythmia—Epirubicin—breast cancer	1.26e-05	9.33e-05	CcSEcCtD
Sunitinib—Asthenia—Paclitaxel—breast cancer	1.26e-05	9.31e-05	CcSEcCtD
Sunitinib—Decreased appetite—Capecitabine—breast cancer	1.25e-05	9.25e-05	CcSEcCtD
Sunitinib—Alopecia—Epirubicin—breast cancer	1.25e-05	9.22e-05	CcSEcCtD
Sunitinib—Nausea—Gemcitabine—breast cancer	1.24e-05	9.2e-05	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Capecitabine—breast cancer	1.24e-05	9.19e-05	CcSEcCtD
Sunitinib—Fatigue—Capecitabine—breast cancer	1.24e-05	9.18e-05	CcSEcCtD
Sunitinib—Pruritus—Paclitaxel—breast cancer	1.24e-05	9.18e-05	CcSEcCtD
Sunitinib—Mental disorder—Epirubicin—breast cancer	1.24e-05	9.15e-05	CcSEcCtD
Sunitinib—Erythema multiforme—Doxorubicin—breast cancer	1.23e-05	9.13e-05	CcSEcCtD
Sunitinib—Pain—Capecitabine—breast cancer	1.23e-05	9.1e-05	CcSEcCtD
Sunitinib—Constipation—Capecitabine—breast cancer	1.23e-05	9.1e-05	CcSEcCtD
Sunitinib—Erythema—Epirubicin—breast cancer	1.23e-05	9.09e-05	CcSEcCtD
Sunitinib—Malnutrition—Epirubicin—breast cancer	1.23e-05	9.09e-05	CcSEcCtD
Sunitinib—Nausea—Fluorouracil—breast cancer	1.22e-05	9.05e-05	CcSEcCtD
Sunitinib—Eye disorder—Doxorubicin—breast cancer	1.22e-05	9.03e-05	CcSEcCtD
Sunitinib—Gastrointestinal pain—Docetaxel—breast cancer	1.22e-05	8.99e-05	CcSEcCtD
Sunitinib—Anaemia—Methotrexate—breast cancer	1.21e-05	8.98e-05	CcSEcCtD
Sunitinib—Flushing—Doxorubicin—breast cancer	1.21e-05	8.96e-05	CcSEcCtD
Sunitinib—Cardiac disorder—Doxorubicin—breast cancer	1.21e-05	8.96e-05	CcSEcCtD
Sunitinib—Flatulence—Epirubicin—breast cancer	1.21e-05	8.95e-05	CcSEcCtD
Sunitinib—Dysgeusia—Epirubicin—breast cancer	1.2e-05	8.9e-05	CcSEcCtD
Sunitinib—Diarrhoea—Paclitaxel—breast cancer	1.2e-05	8.88e-05	CcSEcCtD
Sunitinib—Back pain—Epirubicin—breast cancer	1.19e-05	8.79e-05	CcSEcCtD
Sunitinib—Angiopathy—Doxorubicin—breast cancer	1.19e-05	8.76e-05	CcSEcCtD
Sunitinib—Muscle spasms—Epirubicin—breast cancer	1.18e-05	8.74e-05	CcSEcCtD
Sunitinib—Immune system disorder—Doxorubicin—breast cancer	1.18e-05	8.72e-05	CcSEcCtD
Sunitinib—Gastrointestinal pain—Capecitabine—breast cancer	1.18e-05	8.71e-05	CcSEcCtD
Sunitinib—Mediastinal disorder—Doxorubicin—breast cancer	1.18e-05	8.71e-05	CcSEcCtD
Sunitinib—Body temperature increased—Docetaxel—breast cancer	1.18e-05	8.69e-05	CcSEcCtD
Sunitinib—Abdominal pain—Docetaxel—breast cancer	1.18e-05	8.69e-05	CcSEcCtD
Sunitinib—Leukopenia—Methotrexate—breast cancer	1.18e-05	8.69e-05	CcSEcCtD
Sunitinib—Chills—Doxorubicin—breast cancer	1.17e-05	8.67e-05	CcSEcCtD
Sunitinib—Arrhythmia—Doxorubicin—breast cancer	1.17e-05	8.63e-05	CcSEcCtD
Sunitinib—ABCB1—female reproductive system—breast cancer	1.16e-05	0.000121	CbGeAlD
Sunitinib—Dizziness—Paclitaxel—breast cancer	1.16e-05	8.58e-05	CcSEcCtD
Sunitinib—Alopecia—Doxorubicin—breast cancer	1.15e-05	8.54e-05	CcSEcCtD
Sunitinib—Cough—Methotrexate—breast cancer	1.15e-05	8.47e-05	CcSEcCtD
Sunitinib—Mental disorder—Doxorubicin—breast cancer	1.14e-05	8.46e-05	CcSEcCtD
Sunitinib—Body temperature increased—Capecitabine—breast cancer	1.14e-05	8.42e-05	CcSEcCtD
Sunitinib—Abdominal pain—Capecitabine—breast cancer	1.14e-05	8.42e-05	CcSEcCtD
Sunitinib—Convulsion—Methotrexate—breast cancer	1.14e-05	8.41e-05	CcSEcCtD
Sunitinib—Malnutrition—Doxorubicin—breast cancer	1.14e-05	8.41e-05	CcSEcCtD
Sunitinib—Erythema—Doxorubicin—breast cancer	1.14e-05	8.41e-05	CcSEcCtD
Sunitinib—ABCB1—adrenal gland—breast cancer	1.14e-05	0.000118	CbGeAlD
Sunitinib—Anaemia—Epirubicin—breast cancer	1.14e-05	8.4e-05	CcSEcCtD
Sunitinib—Flatulence—Doxorubicin—breast cancer	1.12e-05	8.29e-05	CcSEcCtD
Sunitinib—Arthralgia—Methotrexate—breast cancer	1.12e-05	8.27e-05	CcSEcCtD
Sunitinib—Chest pain—Methotrexate—breast cancer	1.12e-05	8.27e-05	CcSEcCtD
Sunitinib—Myalgia—Methotrexate—breast cancer	1.12e-05	8.27e-05	CcSEcCtD
Sunitinib—Vomiting—Paclitaxel—breast cancer	1.12e-05	8.25e-05	CcSEcCtD
Sunitinib—Dysgeusia—Doxorubicin—breast cancer	1.11e-05	8.23e-05	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.11e-05	8.21e-05	CcSEcCtD
Sunitinib—Rash—Paclitaxel—breast cancer	1.11e-05	8.18e-05	CcSEcCtD
Sunitinib—Dermatitis—Paclitaxel—breast cancer	1.11e-05	8.17e-05	CcSEcCtD
Sunitinib—Leukopenia—Epirubicin—breast cancer	1.1e-05	8.13e-05	CcSEcCtD
Sunitinib—Back pain—Doxorubicin—breast cancer	1.1e-05	8.13e-05	CcSEcCtD
Sunitinib—ABCB1—bone marrow—breast cancer	1.1e-05	0.000114	CbGeAlD
Sunitinib—Headache—Paclitaxel—breast cancer	1.1e-05	8.13e-05	CcSEcCtD
Sunitinib—Hypersensitivity—Docetaxel—breast cancer	1.1e-05	8.1e-05	CcSEcCtD
Sunitinib—Muscle spasms—Doxorubicin—breast cancer	1.09e-05	8.08e-05	CcSEcCtD
Sunitinib—Cough—Epirubicin—breast cancer	1.07e-05	7.93e-05	CcSEcCtD
Sunitinib—Asthenia—Docetaxel—breast cancer	1.07e-05	7.89e-05	CcSEcCtD
Sunitinib—Convulsion—Epirubicin—breast cancer	1.06e-05	7.87e-05	CcSEcCtD
Sunitinib—Infection—Methotrexate—breast cancer	1.06e-05	7.87e-05	CcSEcCtD
Sunitinib—Hypertension—Epirubicin—breast cancer	1.06e-05	7.85e-05	CcSEcCtD
Sunitinib—Hypersensitivity—Capecitabine—breast cancer	1.06e-05	7.84e-05	CcSEcCtD
Sunitinib—ABCB1—female gonad—breast cancer	1.06e-05	0.00011	CbGeAlD
Sunitinib—Pruritus—Docetaxel—breast cancer	1.05e-05	7.78e-05	CcSEcCtD
Sunitinib—Nervous system disorder—Methotrexate—breast cancer	1.05e-05	7.77e-05	CcSEcCtD
Sunitinib—Anaemia—Doxorubicin—breast cancer	1.05e-05	7.77e-05	CcSEcCtD
Sunitinib—Thrombocytopenia—Methotrexate—breast cancer	1.05e-05	7.76e-05	CcSEcCtD
Sunitinib—Myalgia—Epirubicin—breast cancer	1.05e-05	7.74e-05	CcSEcCtD
Sunitinib—Arthralgia—Epirubicin—breast cancer	1.05e-05	7.74e-05	CcSEcCtD
Sunitinib—Chest pain—Epirubicin—breast cancer	1.05e-05	7.74e-05	CcSEcCtD
Sunitinib—Nausea—Paclitaxel—breast cancer	1.04e-05	7.71e-05	CcSEcCtD
Sunitinib—Skin disorder—Methotrexate—breast cancer	1.04e-05	7.7e-05	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.04e-05	7.68e-05	CcSEcCtD
Sunitinib—Asthenia—Capecitabine—breast cancer	1.03e-05	7.64e-05	CcSEcCtD
Sunitinib—Dry mouth—Epirubicin—breast cancer	1.02e-05	7.57e-05	CcSEcCtD
Sunitinib—Anorexia—Methotrexate—breast cancer	1.02e-05	7.55e-05	CcSEcCtD
Sunitinib—Pruritus—Capecitabine—breast cancer	1.02e-05	7.53e-05	CcSEcCtD
Sunitinib—Leukopenia—Doxorubicin—breast cancer	1.02e-05	7.53e-05	CcSEcCtD
Sunitinib—Diarrhoea—Docetaxel—breast cancer	1.02e-05	7.52e-05	CcSEcCtD
Sunitinib—Oedema—Epirubicin—breast cancer	1e-05	7.42e-05	CcSEcCtD
Sunitinib—Infection—Epirubicin—breast cancer	9.96e-06	7.37e-05	CcSEcCtD
Sunitinib—Cough—Doxorubicin—breast cancer	9.92e-06	7.34e-05	CcSEcCtD
Sunitinib—Shock—Epirubicin—breast cancer	9.87e-06	7.3e-05	CcSEcCtD
Sunitinib—ABCB1—endocrine gland—breast cancer	9.86e-06	0.000102	CbGeAlD
Sunitinib—Convulsion—Doxorubicin—breast cancer	9.85e-06	7.29e-05	CcSEcCtD
Sunitinib—Diarrhoea—Capecitabine—breast cancer	9.85e-06	7.28e-05	CcSEcCtD
Sunitinib—Nervous system disorder—Epirubicin—breast cancer	9.84e-06	7.27e-05	CcSEcCtD
Sunitinib—Dizziness—Docetaxel—breast cancer	9.83e-06	7.27e-05	CcSEcCtD
Sunitinib—Thrombocytopenia—Epirubicin—breast cancer	9.82e-06	7.26e-05	CcSEcCtD
Sunitinib—Hypertension—Doxorubicin—breast cancer	9.82e-06	7.26e-05	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Methotrexate—breast cancer	9.76e-06	7.22e-05	CcSEcCtD
Sunitinib—Skin disorder—Epirubicin—breast cancer	9.74e-06	7.2e-05	CcSEcCtD
Sunitinib—Insomnia—Methotrexate—breast cancer	9.69e-06	7.17e-05	CcSEcCtD
Sunitinib—Chest pain—Doxorubicin—breast cancer	9.68e-06	7.16e-05	CcSEcCtD
Sunitinib—Arthralgia—Doxorubicin—breast cancer	9.68e-06	7.16e-05	CcSEcCtD
Sunitinib—Myalgia—Doxorubicin—breast cancer	9.68e-06	7.16e-05	CcSEcCtD
Sunitinib—Paraesthesia—Methotrexate—breast cancer	9.62e-06	7.12e-05	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	9.61e-06	7.11e-05	CcSEcCtD
Sunitinib—Anorexia—Epirubicin—breast cancer	9.56e-06	7.07e-05	CcSEcCtD
Sunitinib—Dyspnoea—Methotrexate—breast cancer	9.55e-06	7.07e-05	CcSEcCtD
Sunitinib—Dizziness—Capecitabine—breast cancer	9.52e-06	7.04e-05	CcSEcCtD
Sunitinib—Dry mouth—Doxorubicin—breast cancer	9.47e-06	7e-05	CcSEcCtD
Sunitinib—Vomiting—Docetaxel—breast cancer	9.45e-06	6.99e-05	CcSEcCtD
Sunitinib—Dyspepsia—Methotrexate—breast cancer	9.43e-06	6.98e-05	CcSEcCtD
Sunitinib—Rash—Docetaxel—breast cancer	9.37e-06	6.93e-05	CcSEcCtD
Sunitinib—Dermatitis—Docetaxel—breast cancer	9.37e-06	6.93e-05	CcSEcCtD
Sunitinib—Decreased appetite—Methotrexate—breast cancer	9.32e-06	6.89e-05	CcSEcCtD
Sunitinib—Headache—Docetaxel—breast cancer	9.31e-06	6.89e-05	CcSEcCtD
Sunitinib—Oedema—Doxorubicin—breast cancer	9.28e-06	6.86e-05	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Methotrexate—breast cancer	9.25e-06	6.84e-05	CcSEcCtD
Sunitinib—Fatigue—Methotrexate—breast cancer	9.24e-06	6.83e-05	CcSEcCtD
Sunitinib—Infection—Doxorubicin—breast cancer	9.22e-06	6.82e-05	CcSEcCtD
Sunitinib—Pain—Methotrexate—breast cancer	9.16e-06	6.78e-05	CcSEcCtD
Sunitinib—Vomiting—Capecitabine—breast cancer	9.15e-06	6.77e-05	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Epirubicin—breast cancer	9.14e-06	6.76e-05	CcSEcCtD
Sunitinib—Shock—Doxorubicin—breast cancer	9.13e-06	6.75e-05	CcSEcCtD
Sunitinib—Nervous system disorder—Doxorubicin—breast cancer	9.1e-06	6.73e-05	CcSEcCtD
Sunitinib—Thrombocytopenia—Doxorubicin—breast cancer	9.09e-06	6.72e-05	CcSEcCtD
Sunitinib—Rash—Capecitabine—breast cancer	9.08e-06	6.71e-05	CcSEcCtD
Sunitinib—Insomnia—Epirubicin—breast cancer	9.07e-06	6.71e-05	CcSEcCtD
Sunitinib—Dermatitis—Capecitabine—breast cancer	9.07e-06	6.71e-05	CcSEcCtD
Sunitinib—Headache—Capecitabine—breast cancer	9.02e-06	6.67e-05	CcSEcCtD
Sunitinib—Skin disorder—Doxorubicin—breast cancer	9.01e-06	6.67e-05	CcSEcCtD
Sunitinib—Paraesthesia—Epirubicin—breast cancer	9.01e-06	6.66e-05	CcSEcCtD
Sunitinib—Dyspnoea—Epirubicin—breast cancer	8.94e-06	6.61e-05	CcSEcCtD
Sunitinib—Anorexia—Doxorubicin—breast cancer	8.85e-06	6.54e-05	CcSEcCtD
Sunitinib—Nausea—Docetaxel—breast cancer	8.83e-06	6.53e-05	CcSEcCtD
Sunitinib—Dyspepsia—Epirubicin—breast cancer	8.83e-06	6.53e-05	CcSEcCtD
Sunitinib—Gastrointestinal pain—Methotrexate—breast cancer	8.76e-06	6.48e-05	CcSEcCtD
Sunitinib—Decreased appetite—Epirubicin—breast cancer	8.72e-06	6.45e-05	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Epirubicin—breast cancer	8.66e-06	6.4e-05	CcSEcCtD
Sunitinib—Fatigue—Epirubicin—breast cancer	8.65e-06	6.39e-05	CcSEcCtD
Sunitinib—Pain—Epirubicin—breast cancer	8.58e-06	6.34e-05	CcSEcCtD
Sunitinib—Constipation—Epirubicin—breast cancer	8.58e-06	6.34e-05	CcSEcCtD
Sunitinib—Nausea—Capecitabine—breast cancer	8.55e-06	6.32e-05	CcSEcCtD
Sunitinib—Abdominal pain—Methotrexate—breast cancer	8.47e-06	6.27e-05	CcSEcCtD
Sunitinib—Body temperature increased—Methotrexate—breast cancer	8.47e-06	6.27e-05	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Doxorubicin—breast cancer	8.45e-06	6.25e-05	CcSEcCtD
Sunitinib—Insomnia—Doxorubicin—breast cancer	8.39e-06	6.21e-05	CcSEcCtD
Sunitinib—Paraesthesia—Doxorubicin—breast cancer	8.33e-06	6.16e-05	CcSEcCtD
Sunitinib—Dyspnoea—Doxorubicin—breast cancer	8.27e-06	6.12e-05	CcSEcCtD
Sunitinib—Gastrointestinal pain—Epirubicin—breast cancer	8.2e-06	6.06e-05	CcSEcCtD
Sunitinib—Dyspepsia—Doxorubicin—breast cancer	8.17e-06	6.04e-05	CcSEcCtD
Sunitinib—Decreased appetite—Doxorubicin—breast cancer	8.07e-06	5.97e-05	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Doxorubicin—breast cancer	8.01e-06	5.92e-05	CcSEcCtD
Sunitinib—Fatigue—Doxorubicin—breast cancer	8e-06	5.92e-05	CcSEcCtD
Sunitinib—Constipation—Doxorubicin—breast cancer	7.94e-06	5.87e-05	CcSEcCtD
Sunitinib—Pain—Doxorubicin—breast cancer	7.94e-06	5.87e-05	CcSEcCtD
Sunitinib—Body temperature increased—Epirubicin—breast cancer	7.93e-06	5.86e-05	CcSEcCtD
Sunitinib—Abdominal pain—Epirubicin—breast cancer	7.93e-06	5.86e-05	CcSEcCtD
Sunitinib—Hypersensitivity—Methotrexate—breast cancer	7.9e-06	5.84e-05	CcSEcCtD
Sunitinib—Asthenia—Methotrexate—breast cancer	7.69e-06	5.69e-05	CcSEcCtD
Sunitinib—Gastrointestinal pain—Doxorubicin—breast cancer	7.59e-06	5.61e-05	CcSEcCtD
Sunitinib—Pruritus—Methotrexate—breast cancer	7.58e-06	5.61e-05	CcSEcCtD
Sunitinib—Hypersensitivity—Epirubicin—breast cancer	7.39e-06	5.46e-05	CcSEcCtD
Sunitinib—Abdominal pain—Doxorubicin—breast cancer	7.34e-06	5.42e-05	CcSEcCtD
Sunitinib—Body temperature increased—Doxorubicin—breast cancer	7.34e-06	5.42e-05	CcSEcCtD
Sunitinib—Diarrhoea—Methotrexate—breast cancer	7.33e-06	5.42e-05	CcSEcCtD
Sunitinib—Asthenia—Epirubicin—breast cancer	7.2e-06	5.32e-05	CcSEcCtD
Sunitinib—Pruritus—Epirubicin—breast cancer	7.1e-06	5.25e-05	CcSEcCtD
Sunitinib—Dizziness—Methotrexate—breast cancer	7.09e-06	5.24e-05	CcSEcCtD
Sunitinib—Diarrhoea—Epirubicin—breast cancer	6.86e-06	5.07e-05	CcSEcCtD
Sunitinib—Hypersensitivity—Doxorubicin—breast cancer	6.84e-06	5.06e-05	CcSEcCtD
Sunitinib—Vomiting—Methotrexate—breast cancer	6.81e-06	5.04e-05	CcSEcCtD
Sunitinib—ABCB1—lymph node—breast cancer	6.81e-06	7.08e-05	CbGeAlD
Sunitinib—Rash—Methotrexate—breast cancer	6.76e-06	5e-05	CcSEcCtD
Sunitinib—Dermatitis—Methotrexate—breast cancer	6.75e-06	4.99e-05	CcSEcCtD
Sunitinib—Headache—Methotrexate—breast cancer	6.71e-06	4.96e-05	CcSEcCtD
Sunitinib—Asthenia—Doxorubicin—breast cancer	6.66e-06	4.92e-05	CcSEcCtD
Sunitinib—Dizziness—Epirubicin—breast cancer	6.63e-06	4.9e-05	CcSEcCtD
Sunitinib—Pruritus—Doxorubicin—breast cancer	6.57e-06	4.86e-05	CcSEcCtD
Sunitinib—Vomiting—Epirubicin—breast cancer	6.38e-06	4.72e-05	CcSEcCtD
Sunitinib—Nausea—Methotrexate—breast cancer	6.37e-06	4.71e-05	CcSEcCtD
Sunitinib—Diarrhoea—Doxorubicin—breast cancer	6.35e-06	4.7e-05	CcSEcCtD
Sunitinib—Rash—Epirubicin—breast cancer	6.32e-06	4.68e-05	CcSEcCtD
Sunitinib—Dermatitis—Epirubicin—breast cancer	6.32e-06	4.67e-05	CcSEcCtD
Sunitinib—Headache—Epirubicin—breast cancer	6.28e-06	4.65e-05	CcSEcCtD
Sunitinib—Dizziness—Doxorubicin—breast cancer	6.14e-06	4.54e-05	CcSEcCtD
Sunitinib—Nausea—Epirubicin—breast cancer	5.96e-06	4.41e-05	CcSEcCtD
Sunitinib—Vomiting—Doxorubicin—breast cancer	5.9e-06	4.36e-05	CcSEcCtD
Sunitinib—Rash—Doxorubicin—breast cancer	5.85e-06	4.33e-05	CcSEcCtD
Sunitinib—Dermatitis—Doxorubicin—breast cancer	5.85e-06	4.32e-05	CcSEcCtD
Sunitinib—Headache—Doxorubicin—breast cancer	5.81e-06	4.3e-05	CcSEcCtD
Sunitinib—Nausea—Doxorubicin—breast cancer	5.51e-06	4.08e-05	CcSEcCtD
Sunitinib—FYN—Immune System—HRAS—breast cancer	1.33e-07	8.49e-07	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TGFB1—breast cancer	1.33e-07	8.48e-07	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TGFB1—breast cancer	1.33e-07	8.48e-07	CbGpPWpGaD
Sunitinib—FYN—Disease—PIK3CA—breast cancer	1.33e-07	8.47e-07	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—EGFR—breast cancer	1.33e-07	8.47e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MMP9—breast cancer	1.32e-07	8.46e-07	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—IL6—breast cancer	1.32e-07	8.46e-07	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—IL6—breast cancer	1.32e-07	8.46e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CYP1A1—breast cancer	1.32e-07	8.46e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—IL6—breast cancer	1.32e-07	8.46e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—HRAS—breast cancer	1.32e-07	8.45e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—IL6—breast cancer	1.32e-07	8.43e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CDKN1A—breast cancer	1.32e-07	8.43e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—PIK3CA—breast cancer	1.32e-07	8.43e-07	CbGpPWpGaD
Sunitinib—KIT—Disease—AKT1—breast cancer	1.32e-07	8.42e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MMP9—breast cancer	1.32e-07	8.42e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PTEN—breast cancer	1.32e-07	8.41e-07	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—AKT1—breast cancer	1.32e-07	8.41e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—ERCC2—breast cancer	1.31e-07	8.39e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CDKN1A—breast cancer	1.31e-07	8.39e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PTEN—breast cancer	1.31e-07	8.37e-07	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—KRAS—breast cancer	1.31e-07	8.35e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—HRAS—breast cancer	1.31e-07	8.33e-07	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—EGFR—breast cancer	1.3e-07	8.32e-07	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—EGFR—breast cancer	1.3e-07	8.32e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MAPK3—breast cancer	1.3e-07	8.3e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—SRC—breast cancer	1.3e-07	8.29e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CCND1—breast cancer	1.3e-07	8.28e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MAPK3—breast cancer	1.3e-07	8.28e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—JUN—breast cancer	1.29e-07	8.27e-07	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—IL6—breast cancer	1.29e-07	8.24e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MAPK8—breast cancer	1.29e-07	8.23e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CTNNB1—breast cancer	1.28e-07	8.2e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MAPK8—breast cancer	1.28e-07	8.18e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP17A1—breast cancer	1.28e-07	8.17e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—AKT1—breast cancer	1.28e-07	8.16e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—HRAS—breast cancer	1.27e-07	8.13e-07	CbGpPWpGaD
Sunitinib—FYN—Immune System—IL6—breast cancer	1.27e-07	8.13e-07	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PTEN—breast cancer	1.27e-07	8.11e-07	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—KRAS—breast cancer	1.27e-07	8.1e-07	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—AKT1—breast cancer	1.27e-07	8.1e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—SRC—breast cancer	1.27e-07	8.09e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ENO1—breast cancer	1.27e-07	8.09e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTGS1—breast cancer	1.27e-07	8.09e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—IL6—breast cancer	1.27e-07	8.08e-07	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—PIK3CA—breast cancer	1.27e-07	8.08e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—VEGFA—breast cancer	1.26e-07	8.08e-07	CbGpPWpGaD
Sunitinib—JAK2—Immune System—HRAS—breast cancer	1.26e-07	8.07e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MYC—breast cancer	1.26e-07	8.07e-07	CbGpPWpGaD
Sunitinib—JAK2—Disease—PIK3CA—breast cancer	1.26e-07	8.06e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TGFB1—breast cancer	1.26e-07	8.05e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MYC—breast cancer	1.26e-07	8.05e-07	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—AKT1—breast cancer	1.26e-07	8.05e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MMP9—breast cancer	1.26e-07	8.04e-07	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PTEN—breast cancer	1.26e-07	8.04e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TGFB1—breast cancer	1.26e-07	8.03e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CDKN1A—breast cancer	1.25e-07	8.01e-07	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—KRAS—breast cancer	1.25e-07	8e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—STAT3—breast cancer	1.25e-07	8e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PTEN—breast cancer	1.25e-07	8e-07	CbGpPWpGaD
Sunitinib—FGFR1—Disease—AKT1—breast cancer	1.25e-07	7.99e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—IL6—breast cancer	1.25e-07	7.98e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—AKT1—breast cancer	1.25e-07	7.97e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—AKT1—breast cancer	1.25e-07	7.97e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP2D6—breast cancer	1.24e-07	7.93e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—EGFR—breast cancer	1.24e-07	7.89e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—MTHFR—breast cancer	1.23e-07	7.89e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—VEGFA—breast cancer	1.23e-07	7.88e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—EGFR—breast cancer	1.23e-07	7.87e-07	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—KRAS—breast cancer	1.23e-07	7.86e-07	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—KRAS—breast cancer	1.23e-07	7.86e-07	CbGpPWpGaD
Sunitinib—FYN—Disease—HRAS—breast cancer	1.23e-07	7.84e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MAPK8—breast cancer	1.22e-07	7.82e-07	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—breast cancer	1.22e-07	7.82e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—STAT3—breast cancer	1.22e-07	7.8e-07	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—AKT1—breast cancer	1.22e-07	7.8e-07	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—AKT1—breast cancer	1.22e-07	7.8e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—SRC—breast cancer	1.22e-07	7.8e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—AKT1—breast cancer	1.22e-07	7.8e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—HRAS—breast cancer	1.22e-07	7.8e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—IL6—breast cancer	1.22e-07	7.78e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—NCOA2—breast cancer	1.22e-07	7.78e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—AKT1—breast cancer	1.22e-07	7.78e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—SRC—breast cancer	1.21e-07	7.76e-07	CbGpPWpGaD
Sunitinib—JAK2—Immune System—IL6—breast cancer	1.21e-07	7.73e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CD—breast cancer	1.21e-07	7.72e-07	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—PIK3CA—breast cancer	1.2e-07	7.67e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MAPK3—breast cancer	1.2e-07	7.64e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—ALB—breast cancer	1.19e-07	7.62e-07	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—AKT1—breast cancer	1.19e-07	7.61e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—VEGFA—breast cancer	1.19e-07	7.6e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—VEGFA—breast cancer	1.18e-07	7.56e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—FASN—breast cancer	1.18e-07	7.55e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—STAT3—breast cancer	1.18e-07	7.52e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—BCHE—breast cancer	1.18e-07	7.52e-07	CbGpPWpGaD
Sunitinib—FYN—Disease—IL6—breast cancer	1.18e-07	7.5e-07	CbGpPWpGaD
Sunitinib—FYN—Immune System—AKT1—breast cancer	1.17e-07	7.5e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—STAT3—breast cancer	1.17e-07	7.48e-07	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—HRAS—breast cancer	1.17e-07	7.48e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—IL6—breast cancer	1.17e-07	7.46e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—AKT1—breast cancer	1.17e-07	7.46e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—KRAS—breast cancer	1.17e-07	7.46e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MAPK3—breast cancer	1.17e-07	7.46e-07	CbGpPWpGaD
Sunitinib—JAK2—Disease—HRAS—breast cancer	1.17e-07	7.45e-07	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—PIK3CA—breast cancer	1.17e-07	7.44e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—KRAS—breast cancer	1.16e-07	7.44e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MYC—breast cancer	1.16e-07	7.43e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—SLC5A5—breast cancer	1.16e-07	7.43e-07	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—breast cancer	1.16e-07	7.42e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—SRC—breast cancer	1.16e-07	7.41e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TGFB1—breast cancer	1.16e-07	7.41e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—AKT1—breast cancer	1.15e-07	7.36e-07	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—PIK3CA—breast cancer	1.15e-07	7.35e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—NOS3—breast cancer	1.14e-07	7.29e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CAV1—breast cancer	1.14e-07	7.27e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—EGFR—breast cancer	1.14e-07	7.27e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MYC—breast cancer	1.14e-07	7.25e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TGFB1—breast cancer	1.13e-07	7.23e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—VEGFA—breast cancer	1.13e-07	7.22e-07	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—PIK3CA—breast cancer	1.13e-07	7.22e-07	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—PIK3CA—breast cancer	1.13e-07	7.22e-07	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—breast cancer	1.13e-07	7.2e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MAPK3—breast cancer	1.13e-07	7.19e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—AKT1—breast cancer	1.12e-07	7.18e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—NQO1—breast cancer	1.12e-07	7.17e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—SLC2A1—breast cancer	1.12e-07	7.17e-07	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—IL6—breast cancer	1.12e-07	7.16e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—STAT3—breast cancer	1.12e-07	7.15e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MAPK3—breast cancer	1.12e-07	7.15e-07	CbGpPWpGaD
Sunitinib—JAK2—Disease—IL6—breast cancer	1.12e-07	7.13e-07	CbGpPWpGaD
Sunitinib—JAK2—Immune System—AKT1—breast cancer	1.12e-07	7.13e-07	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—breast cancer	1.11e-07	7.11e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—EGFR—breast cancer	1.11e-07	7.09e-07	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—HRAS—breast cancer	1.11e-07	7.09e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MYC—breast cancer	1.09e-07	6.99e-07	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—breast cancer	1.09e-07	6.98e-07	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—breast cancer	1.09e-07	6.98e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TGFB1—breast cancer	1.09e-07	6.97e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MYC—breast cancer	1.09e-07	6.95e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TGFB1—breast cancer	1.09e-07	6.94e-07	CbGpPWpGaD
Sunitinib—FYN—Disease—AKT1—breast cancer	1.08e-07	6.92e-07	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—HRAS—breast cancer	1.08e-07	6.89e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—AKT1—breast cancer	1.08e-07	6.89e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP1B1—breast cancer	1.08e-07	6.88e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—KRAS—breast cancer	1.08e-07	6.87e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—PIK3CA—breast cancer	1.07e-07	6.85e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—EGFR—breast cancer	1.07e-07	6.84e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—PIK3CA—breast cancer	1.07e-07	6.83e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MAPK3—breast cancer	1.07e-07	6.83e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—EGFR—breast cancer	1.06e-07	6.8e-07	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—HRAS—breast cancer	1.06e-07	6.8e-07	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—IL6—breast cancer	1.06e-07	6.79e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—HSP90AA1—breast cancer	1.06e-07	6.74e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CB—breast cancer	1.05e-07	6.73e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—KRAS—breast cancer	1.05e-07	6.7e-07	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—HRAS—breast cancer	1.05e-07	6.68e-07	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—HRAS—breast cancer	1.05e-07	6.68e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTGS2—breast cancer	1.04e-07	6.67e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MYC—breast cancer	1.04e-07	6.64e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TGFB1—breast cancer	1.04e-07	6.63e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—breast cancer	1.04e-07	6.63e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CG—breast cancer	1.04e-07	6.63e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—breast cancer	1.04e-07	6.61e-07	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—AKT1—breast cancer	1.03e-07	6.6e-07	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—IL6—breast cancer	1.03e-07	6.59e-07	CbGpPWpGaD
Sunitinib—JAK2—Disease—AKT1—breast cancer	1.03e-07	6.58e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—NCOA1—breast cancer	1.03e-07	6.56e-07	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—IL6—breast cancer	1.02e-07	6.51e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—EGFR—breast cancer	1.02e-07	6.5e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—STK11—breast cancer	1.01e-07	6.46e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP19A1—breast cancer	1.01e-07	6.46e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—KRAS—breast cancer	1.01e-07	6.46e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—KRAS—breast cancer	1.01e-07	6.42e-07	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—IL6—breast cancer	1e-07	6.39e-07	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—IL6—breast cancer	1e-07	6.39e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—HRAS—breast cancer	9.93e-08	6.34e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—HRAS—breast cancer	9.9e-08	6.32e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—PIK3CA—breast cancer	9.88e-08	6.31e-07	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—AKT1—breast cancer	9.81e-08	6.26e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—PIK3CA—breast cancer	9.64e-08	6.16e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—KRAS—breast cancer	9.61e-08	6.14e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—breast cancer	9.56e-08	6.1e-07	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—AKT1—breast cancer	9.52e-08	6.08e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—IL6—breast cancer	9.5e-08	6.07e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—IL6—breast cancer	9.48e-08	6.05e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—COMT—breast cancer	9.41e-08	6.01e-07	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—AKT1—breast cancer	9.4e-08	6e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GSTP1—breast cancer	9.37e-08	5.98e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—breast cancer	9.33e-08	5.96e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PIK3CA—breast cancer	9.29e-08	5.93e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PIK3CA—breast cancer	9.24e-08	5.9e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—HMOX1—breast cancer	9.24e-08	5.9e-07	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—AKT1—breast cancer	9.23e-08	5.9e-07	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—AKT1—breast cancer	9.23e-08	5.9e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ITPR1—breast cancer	9.22e-08	5.89e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—HRAS—breast cancer	9.14e-08	5.84e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CD—breast cancer	9.12e-08	5.82e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTEN—breast cancer	9.1e-08	5.81e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—ALB—breast cancer	9e-08	5.75e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—breast cancer	8.99e-08	5.74e-07	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PIK3CA—breast cancer	8.96e-08	5.72e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—breast cancer	8.94e-08	5.71e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—HRAS—breast cancer	8.92e-08	5.7e-07	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PIK3CA—breast cancer	8.88e-08	5.67e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ABCB1—breast cancer	8.87e-08	5.66e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PIK3CA—breast cancer	8.83e-08	5.64e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—AKT1—breast cancer	8.76e-08	5.6e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—IL6—breast cancer	8.75e-08	5.59e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—AKT1—breast cancer	8.74e-08	5.58e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—TYMS—breast cancer	8.71e-08	5.56e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—NOS3—breast cancer	8.61e-08	5.5e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PLA2G4A—breast cancer	8.61e-08	5.5e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—NCOR1—breast cancer	8.61e-08	5.5e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GSTM1—breast cancer	8.61e-08	5.5e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—HRAS—breast cancer	8.6e-08	5.49e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—HRAS—breast cancer	8.55e-08	5.46e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—breast cancer	8.54e-08	5.46e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—IL6—breast cancer	8.54e-08	5.45e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GPX1—breast cancer	8.24e-08	5.26e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—IL6—breast cancer	8.23e-08	5.25e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—IL6—breast cancer	8.18e-08	5.23e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—HRAS—breast cancer	8.17e-08	5.22e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP1A1—breast cancer	8.16e-08	5.21e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ERCC2—breast cancer	8.09e-08	5.17e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—AKT1—breast cancer	8.07e-08	5.15e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CB—breast cancer	7.95e-08	5.08e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTGS2—breast cancer	7.88e-08	5.03e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—AKT1—breast cancer	7.88e-08	5.03e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IL6—breast cancer	7.82e-08	4.99e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—MTHFR—breast cancer	7.61e-08	4.86e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—AKT1—breast cancer	7.59e-08	4.85e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—AKT1—breast cancer	7.55e-08	4.82e-07	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—AKT1—breast cancer	7.32e-08	4.68e-07	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—AKT1—breast cancer	7.26e-08	4.63e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—AKT1—breast cancer	7.22e-08	4.61e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CAV1—breast cancer	7.02e-08	4.48e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTEN—breast cancer	6.87e-08	4.39e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CA—breast cancer	6.42e-08	4.1e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CG—breast cancer	6.39e-08	4.08e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CD—breast cancer	5.62e-08	3.59e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ALB—breast cancer	5.55e-08	3.54e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—NOS3—breast cancer	5.31e-08	3.39e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—AKT1—breast cancer	5.25e-08	3.35e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CB—breast cancer	4.9e-08	3.13e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTGS2—breast cancer	4.85e-08	3.1e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CA—breast cancer	4.85e-08	3.09e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTEN—breast cancer	4.23e-08	2.7e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—AKT1—breast cancer	3.96e-08	2.53e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CA—breast cancer	2.99e-08	1.91e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—AKT1—breast cancer	2.44e-08	1.56e-07	CbGpPWpGaD
